p.94 抽出テキスト

36. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020;41:3504–20. https://doi.org/10.1093/ eurheartj/ehaa503 37. Ong P, Athanasiadis A, Borgulya G, Vokshi I, Bastiaenen R, Kubik S, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 2014;129:1723–30. https://doi.org/10.1161/ CIRCULATIONAHA.113.004096 38. Feenstra RGT, Boerhout CKM, Woudstra J, Vink CEM, Wittekoek ME, de Waard GA, et al. Presence of coronary endothelial dysfunction, coronary vasospasm, and adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstructive coronary arteries. Circ Cardiovasc Interv 2022;15:e012017. https://doi.org/10.1161/ circinterventions.122.012017 39. Samuels BA, Shah SM, Widmer RJ, Kobayashi Y, Miner SES, Taqueti VR, et al. Comprehensive management of ANOCA, Part 1—definition, patient population, and diagnosis: JACC state-of-the-art review. J Am Coll Cardiol 2023;82:1245–63. https://doi.org/10.1016/j.jacc.2023.06.043 40. Smilowitz NR, Prasad M, Widmer RJ, Toleva O, Quesada O, Sutton NR, et al. Comprehensive management of ANOCA, Part 2—program development, treatment, and research initiatives: JACC state-of-the-art review. J Am Coll Cardiol 2023;82: 1264–79. https://doi.org/10.1016/j.jacc.2023.06.044 41. Ong P, Safdar B, Seitz A, Hubert A, Beltrame JF, Prescott E. Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovasc Res 2020;116:841–55. https://doi. org/10.1093/cvr/cvz339 42. Feenstra RGT, Seitz A, Boerhout CKM, de Winter RJ, Ong P, Beijk MAM, et al. Reference values for intracoronary Doppler flow velocity-derived hyperaemic microvascular resistance index. Int J Cardiol 2023;371:16–20. https://doi.org/10.1016/j.ijcard. 2022.09.054 43. Jansen TPJ, Konst RE, Elias-Smale SE, van den Oord SC, Ong P, de Vos AMJ, et al. Assessing microvascular dysfunction in angina with unobstructed coronary arteries: JACC review topic of the week. J Am Coll Cardiol 2021;78:1471–9. https://doi.org/10. 1016/j.jacc.2021.08.028 44. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation 2015;131:19–27. https://doi.org/10.1161/CIRCULATIONAHA.114. 011939 45. Schindler TH, Fearon WF, Pelletier-Galarneau M, Ambrosio G, Sechtem U, Ruddy TD, et al. PET for detection and reporting coronary microvascular dysfunction. JACC Cardiovasc Imaging 2023;16:536–48. https://doi.org/10.1016/j.jcmg.2022.12.015 46. Ong P, Seitz A. Advances in risk stratification of patients with coronary microvascular dysfunction: usefulness of stress perfusion CMR. JACC Cardiovasc Imaging 2021;14: 612–4. https://doi.org/10.1016/j.jcmg.2020.09.036 47. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. New Engl J Med 2020; 382:1395–407. https://doi.org/10.1056/NEJMoa1915922 48. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503–16. https://doi.org/10.1056/NEJMoa070829 49. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991–1001. https://doi.org/10.1056/NEJMoa1205361 50. Spertus JA, Jones PG, Maron DJ, O’Brien SM, Reynolds HR, Rosenberg Y, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 2020;382:1408–19. https://doi.org/10.1056/NEJMoa1916370 51. Creber RM, Dimagli A, Spadaccio C, Myers A, Moscarelli M, Demetres M, et al. Effect of coronary artery bypass grafting on quality of life: a meta-analysis of randomized trials. Eur Heart J Qual Care Clin Outcomes 2022;8:259–68. https://doi.org/10.1093/ ehjqcco/qcab075 52. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina. New Engl J Med 2023;389:2319–30. https://doi.org/10.1056/NEJMoa2310610 53. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364: 1607–16. https://doi.org/10.1056/NEJMoa1100356 54. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374: 1511–20. https://doi.org/10.1056/NEJMoa1602001 55. Navarese EP, Lansky AJ, Kereiakes DJ, Kubica J, Gurbel PA, Gorog DA, et al. Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. Eur Heart J 2021;42:4638–51. https://doi.org/10.1093/eurheartj/ehab246 56. Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O’Brien SM, et al. Survival after invasive or conservative management of stable coronary disease. Circulation 2023; 147:8–19. https://doi.org/10.1161/CIRCULATIONAHA.122.062714 57. Douglas PS, Nanna MG, Kelsey MD, Yow E, Mark DB, Patel MR, et al. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized clinical trial. JAMA Cardiology 2023;8:904–14. https://doi.org/10.1001/jamacardio.2023.2595 58. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. New Engl J Med 1996; 334:1311–5. https://doi.org/10.1056/nejm199605163342007 59. Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, et al. Sex differences in demographics, risk factors, presentation, and noninvasive testing in stable outpatients with suspected coronary artery disease: insights from the PROMISE trial. JACC Cardiovasc Imaging 2016;9:337–46. https://doi.org/10.1016/j.jcmg.2016.02.001 60. Garcia M, Mulvagh SL, Bairey Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res 2016;118:1273–93. https://doi.org/10.1161/ CIRCRESAHA.116.307547 61. Stepinska J, Lettino M, Ahrens I, Bueno H, Garcia-Castrillo L, Khoury A, et al. Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association. Eur Heart J Acute Cardiovasc Care 2020;9:76–89. https://doi.org/10.1177/ 2048872619885346 62. Hoorweg BB, Willemsen RT, Cleef LE, Boogaerts T, Buntinx F, Glatz JFC, et al. Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. Heart 2017;103:1727–32. https://doi.org/10.1136/heartjnl-2016-310905 63. Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, et al. Association of sex with severity of coronary artery disease, ischemia, and symptom burden in patients with moderate or severe ischemia: secondary analysis of the ISCHEMIA randomized clinical trial. JAMA Cardiol 2020;5:773–86. https://doi.org/10.1001/jamacardio. 2020.0822 64. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/ EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ ehz455 65. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of patients with acute coronary syndromes. Eur Heart J 2023;44:3720–826. https://doi.org/10.1093/eurheartj/ehad191 66. Campeau L. Letter: grading of angina pectoris. Circulation 1976;54:522–3. https://doi. org/10.1161/circ.54.3.947585 67. Fiol-Sala M, Birnbaum J, Nikus K, Bayés de Luna A. Electrocardiography in Ischemic Heart Disease. Hoboken, NJ: Wiley Blackwell, 2019. 68. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham study. Am Heart J 1983;106:389–96. https://doi.org/10. 1016/0002-8703(83)90208-9 69. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation 2003;108:1263–77. https://doi.org/10.1161/01.CIR.0000088001.59265.EE 70. Androulakis A, Aznaouridis KA, Aggeli CJ, Roussakis GN, Michaelides AP, Kartalis AN, et al. Transient ST-segment depression during paroxysms of atrial fibrillation in otherwise normal individuals: relation with underlying coronary artery disease. J Am Coll Cardiol 2007;50:1909–11. https://doi.org/10.1016/j.jacc.2007.08.005 71. Guo Y, Zhang L, Wang C, Zhao Y, Chen W, Gao M, et al. Medical treatment and longterm outcome of chronic atrial fibrillation in the aged with chest distress: a retrospective analysis versus sinus rhythm. Clin Interv Aging 2011;6:193–8. https://doi.org/10.2147/ CIA.S21775 72. Nucifora G, Schuijf JD, van Werkhoven JM, Trines SA, Kajander S, Tops LF, et al. Relationship between obstructive coronary artery disease and abnormal stress testing in patients with paroxysmal or persistent atrial fibrillation. Int J Cardiovasc Imaging 2011; 27:777–85. https://doi.org/10.1007/s10554-010-9725-x 73. Beltrame JF, Crea F, Kaski JC, Ogawa H, Ong P, Sechtem U, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J 2017;38:2565–8. https://doi.org/10.1093/eurheartj/ehv351 74. Forslund L, Hjemdahl P, Held C, Björkander I, Eriksson SV, Rehnqvist N. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. Eur Heart J 1998;19:578–87. https://doi.org/10.1053/euhj.1997.0819 75. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997;95:2037–43. https://doi.org/10.1161/01.cir.95.8.2037 76. Stone PH, Chaitman BR, Forman S, Andrews TC, Bittner V, Bourassa MG, et al. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by one year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). Am J Cardiol 1997;80:1395–401. https://doi.org/10.1016/s0002-9149(97)00706-6 77. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026